Final Results of the Prospective ADVATE(®) Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII

INTRODUCTION: Neutralizing antibodies to coagulation factor VIII (FVIII) remain a major complication associated with FVIII replacement therapy. AIM: To assess safety and efficacy of immune tolerance induction (ITI) therapy with ADVATE(®) (antihemophilic factor [recombinant] [rAHF]) in patients who p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Amy D, Fernandez, Alejandro, Teitel, Jerome, Botha, Jaco, Khair, Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612659/
https://www.ncbi.nlm.nih.gov/pubmed/34849043
http://dx.doi.org/10.2147/JBM.S329883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612659/
https://www.ncbi.nlm.nih.gov/pubmed/34849043
http://dx.doi.org/10.2147/JBM.S329883

Ejemplares similares